Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
pubmed:
11
8
2020
medline:
20
2
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
: Fat gain is reported in integrase strand transfer inhibitors exposed persons living with HIV. We investigated in 165 persons living with HIV (117 men/48 women), included in the 96-week ANRS-163-ETRAL trial and switched to raltegravir/etravirine, the impact of sex, menopausal status and ovarian reserve (detectable anti-Müllerian hormone). From baseline to 48/96 weeks, women with ovarian reserve were protected from raltegravir/etravirine-induced weight/fat gain and associated insulin-resistance while peri/postmenopausal women increased weight, fat and insulin resistance as did men. The functional ovarian status could protect against raltegravir/etravirine-induced weight gain.
Identifiants
pubmed: 32773470
doi: 10.1097/QAD.0000000000002644
pii: 00002030-202010010-00022
doi:
Substances chimiques
Anti-HIV Agents
0
HIV Integrase Inhibitors
0
Nitriles
0
Pyrimidines
0
etravirine
0C50HW4FO1
Raltegravir Potassium
43Y000U234
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1859-1862Commentaires et corrections
Type : CommentIn
Références
Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis 2020; 33:1019.
Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers 2020; 6:48.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med 2019; 381:803815.
Burns JE, Stirrup OT, Dunn D, Runcie-Unger I, Milinkovic A, Candfield S, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. AIDS 2020; 34:109114.
Mugglin C. Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV cohort study. HIV Med 2019; 20 (S9):PS3/5.
Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis 2020; doi: 10.1093/cid/ciaa177.
doi: 10.1093/cid/ciaa177
Kerchberger AM, Sheth AN, Angert CD, Mehta CC, Summers NA, Ofotokun I, et al. Weight gain associated with integrase stand transfer inhibitor use in women. Clin Infect Dis 2019; doi: 10.1093/cid/ciz853.
doi: 10.1093/cid/ciz853
Katlama C, Assoumou L, Valantin MA, Soulie C, Martinez E, Beniguel L, et al. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. J Antimicrob Chemother 2019; 74:27422751.
Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 2014; 20:688701.
Fiet J, Le Bouc Y, Guechot J, Helin N, Maubert MA, Farabos D, et al. A liquid chromatography/tandem mass spectometry profile of 16 serum steroids, including 21-deoxycortisol and 21-deoxycorticosterone, for management of congenital adrenal hyperplasia. J Endocr Soc 2017; 1:186201.
Erlandson KM, Zhang L, Lake JE, Schrack J, Althoff K, Sharma A, et al. Changes in weight and weight distribution across the lifespan among HIV-infected and -uninfected men and women. Medicine (Baltimore) 2016; 95:e5399.
Ambikairajah A, Walsh E, Tabatabaei-Jafari H, Cherbuin N. Fat mass changes during menopause: a metaanalysis. Am J Obstet Gynecol 2019; 221:393409.e50.
Nguyen TTJ, Ma Y, Scherzer R, Adimora AA, Fischl M, French AL, et al. Body composition changes over the menopausal transition in women with and at risk for HIV. Boston:CROI; 2020.